NASDAQ NMS - GLOBAL MARKET · MDGL
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Biotechnology
$516.74
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Analyst data unavailable at compute time
MDGL
Madrigal Pharmaceuticals Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

37/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is MDGL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading MDGL catalysts
About Madrigal Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2007
Employees
915
Country
US

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$516.74
Last session
Day high
$516.74
Last session
Day low
$516.74
Last session
Previous close
$516.74
52W high
$602.83
-14.28% from high
52W low
$412.23
55% of range
Market cap
$11.9B
EPS
$-12.2200
Beta
0.17
Shares out
23.1M
Avg volume
349.3K
VWAP
$516.74
Last session
Price history computed in-house
1W
-1.55%
1M
-5.10%
3M
-1.44%
1Y
+24.61%
YTD
-11.26%
SMA 50 $522.83 · below
SMA 200 $513.86 · above
52W position 55%

MDGL overview

Veridion Score
37
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
1
Daniel Goldman · Sale
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around MDGL.Congress disclosuresOpen receipt and filing context for MDGL.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading MDGL Form 4 filings
Public disclosures

Congress activity in MDGL

Congress trackerOpen ticker disclosure ledger →
Federal contracts

MDGL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MDGL in this window.
Lobbying spend

MDGL lobbying filings, year to date.

Registered lobbying filings matched to Madrigal Pharmaceuticals Inc.

$1.3M
Refresh interval: 12hSource: LDA disclosure filings
Medicare/Medicaid Health IssuesPharmacy
Filing
$380.0K
MADRIGAL PHARMACEUTICALS INC.

MADRIGAL PHARMACEUTICALS, INC.

Jul 20, 2026
Filing
$380.0K
MADRIGAL PHARMACEUTICALS INC.

MADRIGAL PHARMACEUTICALS, INC.

Apr 24, 2026
Filing
$280.0K
MADRIGAL PHARMACEUTICALS INC.

MADRIGAL PHARMACEUTICALS, INC.

Jan 22, 2026
Loading news for MDGL
Analyst ratings
Sovereign unlock shows live analyst consensus for MDGL.
Options
Sovereign unlock shows live options positioning for MDGL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.